Published in Eur J Cancer on February 01, 2005
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis (2011) 1.05
In utero exposure to low doses of environmental pollutants disrupts fetal ovarian development in sheep. Mol Hum Reprod (2008) 0.99
The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia (2011) 0.99
The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med (2008) 0.97
Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer (2008) 0.88
The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci (2013) 0.88
An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics (2009) 0.85
Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol (2012) 0.79
The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells. Lab Invest (2015) 0.77
Gelsolin regulates proliferation, apoptosis, migration and invasion in human oral carcinoma cells. Oncol Lett (2015) 0.77
Cellular transcriptomics: gelsolin negatively regulates the expression of apoptosis-associated genes and inhibits apoptosis in hepatocarcinoma cells. Int J Clin Exp Pathol (2015) 0.76
Proteomic Analysis of Fetal Ovaries Reveals That Primordial Follicle Formation and Transition Are Differentially Regulated. Biomed Res Int (2017) 0.75
Quantitative proteomic analysis of serum from pregnant women carrying a fetus with conotruncal heart defect using isobaric tags for relative and absolute quantitation (iTRAQ) labeling. PLoS One (2014) 0.75
Gelsolin suppresses gastric cancer metastasis through inhibition of PKR-p38 signaling. Oncotarget (2016) 0.75
Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. Oncol Lett (2017) 0.75
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol (2008) 3.12
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One (2012) 2.85
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res (2006) 2.68
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell (2011) 2.47
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res (2008) 2.36
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol (2008) 1.89
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol (2010) 1.81
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res (2009) 1.75
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol (2011) 1.65
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
Pseudo-pseudo Meigs' syndrome. Lancet (2005) 1.63
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res (2010) 1.55
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006) 1.53
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44
Noncompaction myocardium in association with type Ib glycogen storage disease. Pathol Res Pract (2012) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res (2006) 1.40
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res (2005) 1.37
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate (2004) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn (2013) 1.37
Detection and segmentation of cell nuclei in virtual microscopy images: a minimum-model approach. Sci Rep (2012) 1.35
Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol (2010) 1.35
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer (2013) 1.26
Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch (2002) 1.24
Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia (2004) 1.20
Molecular HPV typing as a diagnostic tool to discriminate primary from metastatic squamous cell carcinoma of the lung. Am J Surg Pathol (2009) 1.19
Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol (2007) 1.19
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19